Relmada Therapeutics Inc
NASDAQ:RLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Y
|
Yinyi Co Ltd
SZSE:000981
|
CN |
Relmada Therapeutics Inc
Depreciation & Amortization
Relmada Therapeutics Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Depreciation & Amortization
$7.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Depreciation & Amortization
$4B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
27%
|
|
|
Pfizer Inc
NYSE:PFE
|
Depreciation & Amortization
$6.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Depreciation & Amortization
$5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Depreciation & Amortization
$2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
Relmada Therapeutics Inc
Glance View
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
